Aliases & Classifications for Mood Disorder

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 15 17
Mood Disorders 54 42 44 15 70
Episodic Mood Disorder 12 70
Moody 6

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 44 D019964
NCIt 50 C92200
SNOMED-CT 67 46206005
UMLS 70 C0525045 C1456434

Summaries for Mood Disorder

MedlinePlus : 42 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to acth-secreting pituitary adenoma and dysthymic disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is HMBS (Hydroxymethylbilane Synthase), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Valproic acid and Carbamazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves a disturbance in mood as the predominant underlying feature.

Wikipedia : 73 Mood disorder, also known as mood affective disorders, is a group of conditions where a disturbance in... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 acth-secreting pituitary adenoma 32.4 POMC NR3C1 DRD2 CRH
2 dysthymic disorder 32.3 SLC6A4 POMC MAOA HTR2A HTR1A DRD4
3 schizoaffective disorder 32.2 SLC6A4 HTR2A HTR1A DRD2 DISC2 DISC1
4 delusional disorder 32.2 TH HTR2A HTR1A DRD4 DRD2 DISC1
5 postpartum depression 32.2 SLC6A4 POMC NR3C1 MAOA HTR1A CRH
6 depression 32.1 TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1A
7 bipolar disorder 32.1 TPH1 TH SLC6A4 NR3C1 MAOA HTR2A
8 atypical depressive disorder 32.0 SLC6A4 POMC NR3C1 MAOB MAOA HTR2A
9 endogenous depression 31.9 TPH1 SLC6A4 POMC NR3C1 MAOA HTR2A
10 major depressive disorder 31.9 TPH1 SLC6A4 POMC NR3C1 NPY MAOB
11 mental depression 31.4 TPH1 SLC6A4 POMC NR3C1 MAOA HTR2A
12 bipolar i disorder 31.4 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
13 agoraphobia 31.1 SLC6A4 MAOA HTR2A HTR1A CRH COMT
14 melancholia 31.1 SLC6A4 POMC MAOA HTR2A HTR1A CRH
15 cyclothymic disorder 31.1 SLC6A4 HTR2A DRD4 DRD2 DISC1 COMT
16 personality disorder 31.1 TPH1 TH SLC6A4 NR3C1 MAOB MAOA
17 borderline personality disorder 31.0 TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1B
18 anorexia nervosa 31.0 SLC6A4 POMC NPY MAOA HTR2A HTR1A
19 alcohol use disorder 31.0 SLC6A4 HTR2A HTR1B HTR1A DRD2 CRH
20 post-traumatic stress disorder 31.0 SLC6A4 POMC NR3C1 MAOB MAOA HTR2A
21 tardive dyskinesia 30.9 HTR2A DRD4 DRD2 COMT
22 eating disorder 30.9 SLC6A4 POMC NPY HTR2A DRD2 CRH
23 bulimia nervosa 30.9 SLC6A4 NPY MAOA HTR2A HTR1B DRD4
24 fibromyalgia 30.9 SLC6A4 POMC NPY HTR2A CRH COMT
25 cannabis abuse 30.9 HTR1A DRD4 DRD2 COMT BDNF
26 traumatic brain injury 30.9 DRD2 COMT BDNF
27 substance abuse 30.9 SLC6A4 POMC NPY MAOA HTR2A HTR1B
28 generalized anxiety disorder 30.9 TPH1 SLC6A4 NR3C1 NPY MAOA HTR2A
29 acute stress disorder 30.9 SLC6A4 POMC NR3C1 HTR1A CRH BDNF
30 oppositional defiant disorder 30.9 SLC6A4 MAOA HTR2A HTR1B DRD4 DRD2
31 social phobia 30.8 SLC6A4 MAOA HTR2A HTR1A DRD2 CRH
32 asthma 30.8 SLC6A4 POMC NR3C1 NPY CRH CREB1
33 paine syndrome 30.8 SLC6A4 CRH COMT BDNF
34 wolfram syndrome 30.8 TH CRH COMT
35 separation anxiety disorder 30.8 SLC6A4 MAOA HTR1A DRD4 COMT
36 huntington disease 30.8 TH NPY MAOB MAOA DRD2 CREB1
37 chronic fatigue syndrome 30.8 SLC6A4 POMC NR3C1 MAOA HTR2A HTR1A
38 irritable bowel syndrome 30.8 TPH1 SLC6A4 POMC HTR2A HTR1A CRH
39 psychotic disorder 30.7 TPH1 TH SLC6A4 MAOB MAOA HTR2A
40 obsessive-compulsive personality disorder 30.7 SLC6A4 HTR2A COMT
41 schizophreniform disorder 30.7 HTR2A DRD2 DISC1 COMT BDNF
42 pervasive developmental disorder 30.7 SLC6A4 HTR2A DRD2 DISC1 BDNF
43 sleep disorder 30.7 TH SLC6A4 POMC NPY HTR2A HTR1A
44 restless legs syndrome 30.7 TH SLC6A4 POMC MAOB MAOA DRD4
45 panic disorder 30.7 TPH1 SLC6A4 POMC NPY MAOA HTR2A
46 attention deficit-hyperactivity disorder 30.7 TPH1 TH SLC6A4 NR3C1 NPY MAOB
47 fragile x syndrome 30.6 SLC6A4 MAOA DISC1 BDNF
48 sleep apnea 30.6 SLC6A4 HTR2A BDNF
49 heroin dependence 30.6 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
50 movement disease 30.6 TH MAOB HTR1A DRD2 COMT BDNF

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


alexithymia; psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 BDNF COMT CREB1 CRH DISC1 DRD2
2 homeostasis/metabolism MP:0005376 10.33 BDNF COMT CREB1 CRH DISC1 DRD2
3 cardiovascular system MP:0005385 10.27 COMT CREB1 DISC1 DRD2 HTR1A HTR1B
4 growth/size/body region MP:0005378 10.25 BDNF CREB1 CRH DISC1 DRD2 HMBS
5 endocrine/exocrine gland MP:0005379 10.23 BDNF COMT CREB1 CRH DRD2 HTR1B
6 cellular MP:0005384 10.22 BDNF CREB1 CRH DRD2 HTR1B MAOB
7 nervous system MP:0003631 10.22 BDNF COMT CREB1 CRH DISC1 DRD2
8 adipose tissue MP:0005375 10.13 CRH DRD2 HTR1A HTR1B NPY NR3C1
9 muscle MP:0005369 9.97 CREB1 DRD2 HMBS HTR1B HTR2A NR3C1
10 no phenotypic analysis MP:0003012 9.86 BDNF CRH DRD2 HTR1A HTR1B NR3C1
11 normal MP:0002873 9.81 BDNF CREB1 CRH DRD2 HMBS NPY
12 renal/urinary system MP:0005367 9.61 COMT CRH DRD2 HMBS MAOB NPY
13 respiratory system MP:0005388 9.23 BDNF COMT CREB1 CRH DRD2 NR3C1

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
3
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
4
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
5
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
6
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
8
Ziprasidone Approved Phase 4 146939-27-7 60854
9
Amitriptyline Approved Phase 4 50-48-6 2160
10
Sertraline Approved Phase 4 79617-96-2 68617
11
Lithium carbonate Approved Phase 4 554-13-2
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Atorvastatin Approved Phase 4 134523-00-5 60823
14
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
15
Memantine Approved, Investigational Phase 4 19982-08-2 4054
16
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
17
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
18
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
19
Lorazepam Approved Phase 4 846-49-1 3958
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Clozapine Approved Phase 4 5786-21-0 2818
23
Metformin Approved Phase 4 657-24-9 4091 14219
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
25
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
26
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
27 Anti-Bacterial Agents Phase 4
28 Calciferol Phase 4
29 Monoamine Oxidase Inhibitors Phase 4
30 Amitriptyline, perphenazine drug combination Phase 4
31 Anticonvulsants Phase 4
32 Trace Elements Phase 4
33 Nutrients Phase 4
34 Micronutrients Phase 4
35 Hormones Phase 4
36 Anti-Infective Agents Phase 4
37 Hypnotics and Sedatives Phase 4
38 Anti-Anxiety Agents Phase 4
39 Hypolipidemic Agents Phase 4
40 Antiviral Agents Phase 4
41 Quetiapine Fumarate Phase 4 111974-72-2
42 Estrogens Phase 4
43 Gastrointestinal Agents Phase 4
44 Antiemetics Phase 4
45 Cyclooxygenase Inhibitors Phase 4
46 Fibrinolytic Agents Phase 4
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
48 Antimetabolites Phase 4
49 Anticholesteremic Agents Phase 4
50 Anti-Inflammatory Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 458)
# Name Status NCT ID Phase Drugs
1 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
2 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
3 Minocycline for Bipolar Disorder Completed NCT01514422 Phase 4 Minocycline
4 Prolonging Remission in Depressed Elderly (PRIDE) Completed NCT01028508 Phase 4 lithium and Venlafaxine
5 Brexpiprazole for Bipolar Depression Completed NCT03427892 Phase 4 Brexpiprazole
6 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
7 An Exploratory Study Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar I and II Patients From Valproic Acid to Depakote ER Completed NCT00211250 Phase 4 Valproic Acid and Depakote ER
8 Dynamic Measures of Neurochemistry in Mood Disorders Completed NCT00178828 Phase 4 sertraline;bupropion
9 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
10 Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study Completed NCT00177567 Phase 4 lithium carbonate;Depakote-ER;risperidone;olanzapine;paroxetine;bupropion;lamotrigine;venlafaxine;tranylcypromine;mirtazapine
11 Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Mood Disorders Through Resources Available in Brazilian Public Health Completed NCT02870283 Phase 4 Lithium;Valproic Acid;Carbamazepine
12 Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders Completed NCT01559857 Phase 4 Pioglitazone;Sugar Pill
13 Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms Completed NCT00912535 Phase 4 Quetiapine extended release tablet;Placebo
14 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
15 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
16 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
17 Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans Completed NCT00288782 Phase 4 Mirtazapine
18 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
19 Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial Completed NCT01431092 Phase 4 Placebo;Melatonin
20 The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff Completed NCT01462058 Phase 4 Placebo
21 Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder Completed NCT00502320 Phase 4 Ramelteon;Placebo
22 Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana Completed NCT02593734 Phase 4 olanzapine;risperidone;amitryptaline;fluoxetine
23 Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model Recruiting NCT04685642 Phase 4 Aspirin;Atorvastatin
24 Acoustic Startle Response in Women With Premenstrual Mood Disorders Recruiting NCT02777372 Phase 4 Sertraline
25 Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia Recruiting NCT03860597 Phase 4 Memantine;Placebos
26 A Randomized Controlled Trial of Quetiapine for the Treatment of Youth With Co-occurring Substance Use Disorders and Severe Mood Dysregulation Recruiting NCT02845453 Phase 4 Quetiapine;Placebo
27 An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth Recruiting NCT03911414 Phase 4 Open-label Treatment with Omega-3 Fatty Acids + Inositol;Open-label Treatment with N-acetylcysteine
28 Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder: A Randomized Controlled Trial Recruiting NCT04222816 Phase 4 Lithium Carbonate;Sodium chloride
29 Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial Recruiting NCT04113993 Phase 4 Bazedoxifene Acetate;Placebo
30 Multi-modal Assessment of GABA Function in Psychosis Recruiting NCT04004416 Phase 4 Lorazepam and fMRI
31 Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression Active, not recruiting NCT03993457 Phase 4 Escitalopram;Bupropion
32 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Active, not recruiting NCT03881449 Phase 4
33 A Comparison Study of Combined ECT and Risperidone Versus ECT Alone for Treatment Resistant Depression. Terminated NCT00203723 Phase 4 Risperidone
34 A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder Terminated NCT02140788 Phase 4 Metformin;Fish Oil
35 EnBrace HR for Premenstrual Syndrome (PMS) With Prominent Mood Symptoms (or Menstrual Related Mood Disorders, MRMD) Withdrawn NCT04123483 Phase 4 EnBrace HR Softgel
36 Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723] Withdrawn NCT03278938 Phase 4 bupropion;citalopram
37 Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence Unknown status NCT01714050 Phase 2, Phase 3
38 Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury Completed NCT00704379 Phase 2, Phase 3 Placebo;Sertraline
39 A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension Completed NCT00240721 Phase 3 topiramate
40 Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed NCT00202514 Phase 2, Phase 3 divalproex sodium extended release
41 A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Completed NCT02983188 Phase 2, Phase 3 Berberine;Placebos;Antipsychotic Agents
42 A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents Completed NCT00221468 Phase 3 quetiapine
43 First Experimental Study of Transference Interpretations (FEST) Completed NCT00423462 Phase 2, Phase 3
44 An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects With a Mood Disorder Completed NCT00579982 Phase 3 Lamotrigine
45 Magnetic Seizure Therapy (MST) for the Treatment of Severe Mood Disorder Completed NCT00488748 Phase 3
46 A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol Completed NCT00340379 Phase 2, Phase 3 Ziprasidone;Sertraline;Haloperidol
47 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder Completed NCT00299715 Phase 3 Paliperidone extended-release
48 Prevention of Seasonal Affective Disorder Completed NCT00046449 Phase 3 Investigational Seasonal Affective Disorder (SAD) Drug
49 A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase Completed NCT00046241 Phase 3 Extended-release bupropion hydrochloride
50 A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension Completed NCT00035802 Phase 3 Topiramate;Placebo

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carbamazepine
Divalproex Sodium
lamotrigine
Mood Stabilizer [EPC]
Sodium Valproate
Valproic Acid

Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

40
Brain, Cortex, Prefrontal Cortex, Amygdala, Thyroid, Pituitary, Temporal Lobe

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 17868)
# Title Authors PMID Year
1
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. 61 42
33427944 2021
2
Birth by cesarean section and mood disorders among adolescents of a birth cohort study in northern Brazil. 42 61
33503158 2021
3
Assessment of the Impact of a Daily Rehabilitation Program on Anxiety and Depression Symptoms and the Quality of Life of People with Mental Disorders during the COVID-19 Pandemic. 42
33546511 2021
4
Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. 61 54
20060128 2010
5
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 54 61
19936882 2010
6
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. 61 54
20072116 2010
7
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. 54 61
20043006 2010
8
Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. 54 61
19931869 2010
9
Altered gene expression of histone deacetylases in mood disorder patients. 54 61
19767015 2010
10
Culture-gene coevolution of individualism-collectivism and the serotonin transporter gene. 61 54
19864286 2010
11
Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. 54 61
20010318 2010
12
A possible role of neuropeptide Y in depression and stress. 54 61
19782662 2010
13
Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect. 54 61
19517574 2010
14
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. 61 54
20016223 2010
15
Endocannabinoids and their role in fatty liver disease. 61 54
20460921 2010
16
Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats. 54 61
19576731 2009
17
kappa-Opioid receptor signaling and brain reward function. 54 61
19804796 2009
18
G72/G30 (DAOA) and juvenile-onset mood disorders. 54 61
19089835 2009
19
Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. 61 54
19906241 2009
20
A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. 61 54
19589503 2009
21
Relationships between angry-impulsive personality traits and genetic polymorphisms of the dopamine transporter. 61 54
19368898 2009
22
The role of beta-endorphin in the pathophysiology of major depression. 61 54
19647870 2009
23
Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. 54 61
19584773 2009
24
Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. 61 54
19376528 2009
25
Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. 54 61
19375869 2009
26
Mutation screen and association analysis of the glucocorticoid receptor gene (NR3C1) in childhood-onset mood disorders (COMD). 61 54
19089807 2009
27
Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. 54 61
19224106 2009
28
Management of non-motor complications in Parkinson's disease. 61 54
19711120 2009
29
Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. 61 54
19375070 2009
30
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. 54 61
19233297 2009
31
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. 61 54
19428704 2009
32
Increased risk of suicide attempt in mood disorders and TPH1 genotype. 61 54
18977032 2009
33
Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis. 61 54
19530966 2009
34
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. 61 54
19361869 2009
35
Partial regulation of serotonin transporter function by gamma-synuclein. 54 61
19429025 2009
36
Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. 54 61
18817811 2009
37
Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress. 61 54
18317463 2009
38
Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. 54 61
18704093 2009
39
Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. 61 54
18849121 2009
40
Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. 54 61
18715570 2009
41
Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. 54 61
18976638 2009
42
Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population. 61 54
19224413 2009
43
Disruption of the circadian timing systems: molecular mechanisms in mood disorders. 61 54
19708722 2009
44
Circadian polymorphisms associated with affective disorders. 54 61
19166596 2009
45
[BDNF measurement in stress-related mood disorders: a review of clinical studies]. 54 61
20013430 2009
46
Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. 54 61
19018231 2008
47
Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. 61 54
18574609 2008
48
BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. 61 54
19018714 2008
49
The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. 61 54
19032713 2008
50
Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. 61 54
18664999 2008

Variations for Mood Disorder

ClinVar genetic disease variations for Mood Disorder:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HMBS NM_000190.4(HMBS):c.400del (p.Thr133_Leu134insTer) Deletion Pathogenic 374084 rs1057518886 GRCh37: 11:118960753-118960753
GRCh38: 11:119090043-119090043

Expression for Mood Disorder

Search GEO for disease gene expression data for Mood Disorder.

Pathways for Mood Disorder

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 POMC NR3C1 NPY HTR2A HTR1B HTR1A
2
Show member pathways
12.94 POMC HTR2A DRD2 CRH CREB1 BDNF
3
Show member pathways
12.74 TH MAOB MAOA DRD4 DRD2 CREB1
4
Show member pathways
12.72 TH MAOB MAOA DRD2 CREB1
5 12.57 TPH1 TH POMC NPY HTR1A CREB1
6 12.25 POMC NPY HTR1B HTR1A DRD2 CREB1
8
Show member pathways
11.95 HTR2A HTR1B HTR1A DRD4 DRD2
9
Show member pathways
11.95 TH MAOB MAOA DRD2 CREB1 BDNF
10
Show member pathways
11.86 DRD4 DRD2 CREB1
11 11.86 TPH1 SLC6A4 MAOB MAOA HTR2A HTR1B
12
Show member pathways
11.82 TH DRD4 DRD2
13 11.82 TPH1 TH SLC6A4 NR3C1 MAOA HTR2A
14 11.78 POMC CRH CREB1
15
Show member pathways
11.77 TPH1 MAOB MAOA
16 11.75 TPH1 TH MAOA
17
Show member pathways
11.75 TH MAOB MAOA COMT
18
Show member pathways
11.72 TPH1 MAOB MAOA
19 11.69 POMC NR3C1 CREB1
20
Show member pathways
11.39 TH SLC6A4 MAOA
21
Show member pathways
11.15 SLC6A4 MAOA COMT
22
Show member pathways
11.12 TPH1 TH MAOA COMT
23 11.08 TPH1 SLC6A4 MAOA HTR2A HTR1B HTR1A
24 11.06 TH POMC NPY DRD2
25
Show member pathways
10.89 MAOB MAOA COMT
26 10.88 TH MAOB MAOA COMT
27 10.78 CREB1 BDNF
28
Show member pathways
10.74 MAOB MAOA
29
Show member pathways
10.64 TH SLC6A4 MAOB MAOA HTR1B HTR1A
30 10.43 POMC CRH

GO Terms for Mood Disorder

Cellular components related to Mood Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.87 SLC6A4 NPY HTR2A HTR1A DRD2 DISC1
2 integral component of postsynaptic membrane GO:0099055 9.58 SLC6A4 HTR2A DRD2
3 axon GO:0030424 9.5 TH HTR2A DRD2 DISC1 CREB1 COMT
4 integral component of presynaptic membrane GO:0099056 9.46 SLC6A4 HTR2A HTR1B DRD2
5 G protein-coupled serotonin receptor complex GO:0098666 9.37 HTR2A HTR1B
6 serotonergic synapse GO:0099154 9.26 SLC6A4 HTR1B
7 dendrite GO:0030425 9.23 TH HTR2A HTR1B HTR1A DRD4 DRD2

Biological processes related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 POMC NR3C1 HTR2A HTR1B HTR1A DRD4
2 G protein-coupled receptor signaling pathway GO:0007186 10.19 POMC NPY HTR2A HTR1B HTR1A DRD4
3 response to hypoxia GO:0001666 9.96 TH SLC6A4 DRD2 CREB1
4 cellular calcium ion homeostasis GO:0006874 9.88 HTR2A DRD4 DRD2
5 response to toxic substance GO:0009636 9.87 SLC6A4 MAOB DRD2
6 circadian rhythm GO:0007623 9.87 TPH1 SLC6A4 CREB1
7 chemical synaptic transmission GO:0007268 9.85 NPY HTR2A HTR1B HTR1A DRD4 CRH
8 positive regulation of fat cell differentiation GO:0045600 9.83 TPH1 HTR2A CREB1
9 social behavior GO:0035176 9.83 TH SLC6A4 DRD4
10 regulation of synaptic vesicle exocytosis GO:2000300 9.81 HTR2A HTR1B DRD2
11 response to cocaine GO:0042220 9.81 HTR1B DRD2 CRH
12 response to ethanol GO:0045471 9.8 TH MAOB HTR1B DRD2 CRH
13 response to nicotine GO:0035094 9.79 TH DRD2 CREB1
14 feeding behavior GO:0007631 9.78 NPY HTR1B DRD2
15 response to amphetamine GO:0001975 9.77 TH DRD4 DRD2
16 regulation of dopamine secretion GO:0014059 9.76 HTR2A HTR1B DRD2
17 response to immobilization stress GO:0035902 9.74 TPH1 TH CRH
18 response to corticosterone GO:0051412 9.72 TH MAOB CRH
19 vasoconstriction GO:0042310 9.71 SLC6A4 HTR1B HTR1A
20 neurotransmitter biosynthetic process GO:0042136 9.7 TH SLC6A4
21 catecholamine metabolic process GO:0006584 9.7 MAOA COMT
22 G protein-coupled receptor internalization GO:0002031 9.7 HTR1B DRD2
23 dopamine metabolic process GO:0042417 9.7 DRD4 DRD2 COMT
24 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD4 DRD2
25 cellular response to alkaloid GO:0071312 9.69 TH HTR1B
26 behavior GO:0007610 9.69 HTR2A HTR1B HTR1A
27 regulation of behavior GO:0050795 9.68 HTR1B HTR1A
28 regulation of dopamine metabolic process GO:0042053 9.68 HTR1A DRD4
29 aromatic amino acid family metabolic process GO:0009072 9.68 TPH1 TH
30 behavioral response to ethanol GO:0048149 9.68 DRD4 DRD2
31 hyaloid vascular plexus regression GO:1990384 9.67 TH DRD2
32 drinking behavior GO:0042756 9.67 HTR1B DRD2
33 serotonin receptor signaling pathway GO:0007210 9.67 HTR2A HTR1A
34 behavioral response to cocaine GO:0048148 9.67 HTR2A DRD4 DRD2
35 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.66 HTR1B HTR1A
36 negative regulation of serotonin secretion GO:0014063 9.65 MAOB HTR1B
37 neurotransmitter catabolic process GO:0042135 9.65 MAOB MAOA COMT
38 memory GO:0007613 9.65 TH SLC6A4 HTR2A CREB1 BDNF
39 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.64 DRD4 DRD2
40 response to ether GO:0045472 9.63 TH CRH
41 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 HTR2A HTR1B DRD2
42 response to histamine GO:0034776 9.62 DRD4 DRD2
43 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD4 DRD2
44 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.62 HTR2A HTR1B HTR1A DRD4
45 dopamine catabolic process GO:0042420 9.61 MAOB MAOA COMT
46 regulation of serotonin secretion GO:0014062 9.58 HTR1A CRH
47 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.55 NPY HTR2A HTR1B HTR1A DRD4
48 synaptic transmission, dopaminergic GO:0001963 9.26 TH DRD4 DRD2 CRH
49 response to drug GO:0042493 9.23 TH SLC6A4 MAOB HTR2A DRD2 CRH

Molecular functions related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.47 TPH1 TH SLC6A4 POMC NR3C1 NPY
2 G protein-coupled receptor activity GO:0004930 9.95 NPY HTR2A HTR1B HTR1A DRD4 DRD2
3 signaling receptor binding GO:0005102 9.85 POMC NPY DRD2 CRH BDNF
4 neurotransmitter receptor activity GO:0030594 9.56 HTR2A HTR1B HTR1A DRD4
5 primary amine oxidase activity GO:0008131 9.43 MAOB MAOA
6 dopamine neurotransmitter receptor activity GO:0004952 9.4 DRD4 DRD2
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TH
8 dopamine binding GO:0035240 9.33 TH DRD4 DRD2
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD4 DRD2
10 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR2A HTR1B HTR1A DRD4
11 serotonin binding GO:0051378 8.92 SLC6A4 HTR2A HTR1B HTR1A

Sources for Mood Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....